The drug candidate, trevogrumab, in combination with Novo Nordisk's popular obesity drug Wegovy, chemically known as semaglutide, helped patients preserve muscle and increase fat loss in patients, ...

Novo Nordisk was Europe's most valuable company, with a big lead on obesity drugs with its runaway hits Ozempic and Wegovy.